रिसेड्रोनेट के इंटरैक्शन

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. (पैमिड्रोनेट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

Oxybutynin chloride extended-release tablets should be used with caution in patients who have gastroesophageal reflux and/or who are concurrently taking drugs (such as bisphosphonates) that can cause or exacerbate esophagitis. (ऑक्सीब्यूटिनिन लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

Closely monitor for signs of renal toxicity when XELODA is used concomitantly with nephrotoxic drugs (e.g. platinum salts, irinotecan, methotrexate, intravenous bisphosphonates). (कैपेसिटाबिन लेबल, दवाओं के इंटरैक्शन)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

मैग्नीशियम युक्त सप्लीमेंट और एंटासिड इन दवाओं का अवशोषण कम करते हैं; खुराकों के बीच कम से कम दो घंटे का अंतर रखें। (NIH Office of Dietary Supplements, Magnesium)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (सुनिटिनिब लेबल, चेतावनियां और सावधानियां)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Upper Gastrointestinal Adverse Reactions Risedronate sodium delayed-release, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (एक्सेमेस्टेन लेबल, चेतावनियां और सावधानियां)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Upper Gastrointestinal Adverse Reactions Risedronate sodium delayed-release, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Upper Gastrointestinal Adverse Reactions Risedronate sodium delayed-release, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)